Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases

CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- ("Cosmos Health" or the “Company”) , a diversified, vertically integrated global healthcare group, today announced that Chief Executive Officer Greg Siokas has further increased his ownership in the Company through continued share acquisitions during November 2025.

Specifically, between 19 November and 28 November 2025, Mr. Siokas executed five transactions, acquiring 301,101 shares.

So far in 2025, he has added 3,398,055 shares to his holdings.

Following these acquisitions, his total ownership has increased to 6,459,985 shares of Cosmos Health.

Greg Siokas, CEO of Cosmos Health, stated: “We recently reported record-breaking Q3 2025 results, and I expect this strong momentum to continue into Q4. Despite our all-time-high achievements in quarterly revenue, gross profit and gross margins, driven by robust growth across all core business segments, our valuation remains under pressure.

I have increased my ownership by well over three million shares since the beginning of the year because I firmly believe Cosmos is well positioned to deliver significant value. I remain committed to supporting the Company in every way necessary so that we can achieve our objectives as we expand globally and advance our pipeline of innovative products.”

Information on Mr. Siokas’s Recent Transactions:

Please refer to the filings on Form 4 filed with the SEC and available on the SEC's website for more information about the nature of the transactions, including details such as “Ownership Form”, “Transaction Date”, “Amount”, “Price”, and other relevant information regarding the shares acquired by Mr. Siokas.

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at , , , , , as well as and .

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.

Investor Relations Contact:

BDG Communications